Abstract:
【Abstract】Objective To explore the expression of microRNA-32（miR-32）in multiple myeloma（MM）, and the relationship of its expression with clinical features. Methods The expression levels of miR-32 in bone marrow mono-nuclear cells of MM patients and 20 normal controls were examined by real-time polymerase chain reaction. The association of miR-32 in MM with β2-microglobulin（β2-MG）and Durie-Salmon（D-S）staging was further studied. Results The expression of miR-32 in MM patients（5.29±0.31）was obviously higher than that in normal control（the relative value was set as 1）with statistical differences（P＜0.05）. The expression of miR-32 in relapsed／refractory MM patients was obviously higher than that in newly diagnosed patients（6.86±0.24 vs.4.15±0.29） with statistical significance（P＜0.05）. The expression of miR32 in MM patients after chemotherapy was lower than that before treatment（5.29±0.31 vs. 3.43±0.45），especially in effective group（4.57±0.41 vs.1.92±0.15），showing significant differences（P＜0.05）. There was no statistical differences in ineffective／progress group before and after chemotherapy（P＞0.05）.The expression of miR-32 was associated with D-S staging and β2-MG of MM. Conclusion Expression of miR-32 in MM plays an important role in the development and progression of MM, and is possible to become a predictor of disease progression and efficacy in MM.